Estimation of Infection Force of Hepatitis C Virus Among Drug Users in France

被引:6
|
作者
Kasereka, Selain [1 ]
Le Strat, Yann [2 ]
Leon, Lucie [2 ]
机构
[1] Univ Kinshasa, Kinshasa, DEM REP CONGO
[2] French Natl Publ Hlth Agcy, Sante Publ France, St Maurice, Ile De France, France
来源
RECENT ADVANCES IN NONLINEAR DYNAMICS AND SYNCHRONIZATION: WITH SELECTED APPLICATIONS IN ELECTRICAL ENGINEERING, NEUROCOMPUTING, AND TRANSPORTATION | 2018年 / 109卷
关键词
INJECT DRUGS; PEOPLE; PREVENTION; AUSTRALIA; MORTALITY;
D O I
10.1007/978-3-319-58996-1_15
中图分类号
TM [电工技术]; TN [电子技术、通信技术];
学科分类号
0808 ; 0809 ;
摘要
The spread of diseases is a dynamic and complex phenomenon. In the world, they are due to misery and poverty. To understand epidemiological systems is essential for governments. Since modeling simplifies reality, it is an excellent method. The hepatitis C virus (HCV) infection is common worldwide, and injection drug use remains the major mode of transmission of the disease, especially because of equipment sharing. Consequently, it is crucial to monitor the HCV transmission dynamics over time and to assess the effect of harm reduction measures. The aim of this work is to estimate the force of infection of hepatitis C from two national cross-sectional epidemiological surveys conducted in 2004 and 2011 by the French Institute for Public Health Surveillance and its partners in a drug user population in France. HCV prevalence was estimated according to age and calendar time through fractional polynomials adjusted or not to the HIV serological status and to injected drug users or oral drug users in general. The force of infection was modeled according to an SIS (susceptible-infected-susceptible) compartmental model using ordinary differential equations (ODE) and as a function of the derivative of the prevalence function depending on age, time, HIV serological status, and having injected at least once in their life, from 2000 to 2020. Our model was applied on real and simulated surveys using R and Stata software. The results show that HCV prevalence and the force of infection are linked to age and time, and are very high for drug users who injected at least once in their life and who are simultaneously HCV and HIV infected. Based on this model, we estimated that HCV incidence will continue to decline over the following years. Currently in France, there is no cohort study of the HCV among drug users. The only way to estimate HCV incidence in the French population is to use the only existing two national cross-sectional surveys. Our work provides guidance for researchers to compare several cross-sectional epidemiological surveys among drug users and proposes an alternative method to estimate the force of infection among drug users from cross-sectional surveys in the absence of a cohort.
引用
收藏
页码:319 / 344
页数:26
相关论文
共 50 条
  • [31] Hepatitis B virus infection and vaccination among young injection and non-injection drug users: missed opportunities to prevent infection
    Kuo, I
    Sherman, SG
    Thomas, DL
    Strathdee, SA
    DRUG AND ALCOHOL DEPENDENCE, 2004, 73 (01) : 69 - 78
  • [32] Hepatitis C virus treatment as prevention among injecting drug users: who should we cure first?
    de Vos, Anneke S.
    Prins, Maria
    Kretzschmar, Mirjam E. E.
    ADDICTION, 2015, 110 (06) : 975 - 983
  • [33] Hepatitis C Infection Among Injecting Drug Users in England and Wales (1992-2006): There and Back Again?
    Sweeting, Michael J.
    Hope, Vivian D.
    Hickman, Matthew
    Parry, John V.
    Ncube, Fortune
    Ramsay, Mary E.
    De Angelis, Daniela
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2009, 170 (03) : 352 - 360
  • [34] Prevalence of human immunodeficiency virus and Hepatitis (B & C) among drug users in a tertiary care public hospital
    Asif, Aftab
    Ayub, Sumaira
    Komal, Afreen
    Noor, Shahbaz
    Jalal, Umer
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2019, 35 (02) : 459 - 463
  • [35] Towards hepatitis C elimination in France: Scanvir, an effective model to test and treat drug users on dedicated days
    Debette-Gratien, Marilyne
    Francois, Sandrine
    Chevalier, Catherine
    Alain, Sophie
    Carrier, Paul
    Rigaud, Celine
    Abraham, Bruno
    Burgevin, Anne-Laure
    Courat, Laurent
    Debenes, Bernard
    Koffi, Joseph
    Caux-Nussbaum, Elisabeth
    Zattoni-Leroy, Juliette
    Feuillet-Sow, Gaelle
    Dumont, Quentin
    Nubukpo, Philippe
    Loustaud-Ratti, Veronique
    JOURNAL OF VIRAL HEPATITIS, 2023, 30 (04) : 355 - 361
  • [36] Association of Opioid Agonist Therapy With Lower Incidence of Hepatitis C Virus Infection in Young Adult Injection Drug Users
    Tsui, Judith I.
    Evans, Jennifer L.
    Lum, Paula J.
    Hahn, Judith A.
    Page, Kimberly
    JAMA INTERNAL MEDICINE, 2014, 174 (12) : 1974 - 1981
  • [37] Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study
    Boglione, L.
    Pinna, S. Mornese
    De Nicolo, A.
    Cusato, J.
    Cariti, G.
    Di Perri, G.
    D'Avolio, A.
    JOURNAL OF VIRAL HEPATITIS, 2017, 24 (10) : 850 - 857
  • [38] Hepatitis B, C, and D virus infection showing distinct patterns between injection drug users and the general population
    Chen, Fei
    Zhang, Jian
    Guo, Fengfan
    Wen, Bo
    Luo, Shan
    Yuan, Dongping
    Lin, Yingbiao
    Ou, Wensheng
    Tang, Ping
    Dai, Guozhi
    Li, Fangfang
    Liu, Wenpei
    Qu, Xiaowang
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 (02) : 515 - 520
  • [39] Determinants of stigma among patients with hepatitis C virus infection
    Saine, M. Elle
    Szymczak, Julia E.
    Moore, Tyler M.
    Bamford, Laura P.
    Barg, Frances K.
    Schnittker, Jason
    Holmes, John H.
    Mitra, Nandita
    Lo Re, Vincent, III
    JOURNAL OF VIRAL HEPATITIS, 2020, 27 (11) : 1179 - 1189
  • [40] Attribution of Hepatitis C Virus Seroconversion Risk in Young Injection Drug Users in 5 US Cities
    Hagan, Holly
    Pouget, Enrique R.
    Williams, Ian T.
    Garfein, Richard L.
    Strathdee, Steffanie A.
    Hudson, Sharon M.
    Latka, Mary H.
    Ouellet, Lawrence J.
    JOURNAL OF INFECTIOUS DISEASES, 2010, 201 (03) : 378 - 385